Source: Eur Respir J 2011; 38: 851-860
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Hall S.M., Davie N., Klein N., Haworth S.G.. Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment. Eur Respir J 2011; 38: 851-860

Member's Comments

No comment yet.

Related content which might interest you: Endothelin receptor antagonists in pulmonary arterial hypertension Source: Eur Respir J 2008; 31: 407-415 Year: 2008 Peripheral airway dysfunction persist after endothelin receptor antagonist therapy in patients with idiopathic pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary circulation Year: 2009 Endothelin: setting the scene in PAH Source: Eur Respir Rev 2008; 17: 3-7 Year: 2007 Goal-oriented treatment and combination therapy for pulmonary arterial hypertension Source: Eur Respir J 2005; 26: 858-863 Year: 2005 Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure Source: Eur Respir J 2011; 37: 578-586 Year: 2011 Current medical therapies in pulmonary arterial hypertension Source: Eur Respir Mon 2012; 57: 26-41 Year: 2012 Expression of the serotonin 1b receptor in experimental pulmonary hypertension Source: Eur Respir J 2003; 22: 408-412 Year: 2003 Dual endothelin receptor antagonism: setting standards in PAH Source: Eur Respir Rev 2008; 17: 13-18 Year: 2007 Successful transition from oral prostacyclin analogue (beraprost) to the selective endothelin receptor antagonist (sitaxsentan) therapy in pulmonary arterial hypertension Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment Year: 2007 Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 Source: Eur Respir J 2004; 24: 353-359 Year: 2004 Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2017 – PAH and CTEPH Year: 2017 Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension Source: Eur Respir J 2006 Oct 01;28(4):691-694 Year: 2006 Treatment of early systemic sclerosis associated pulmonary arterial hypertension with endothelin receptor antagonists improves survival Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension Year: 2007 Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy Source: Eur Respir Rev 2009; 18: 253-259 Year: 2009 Pulmonary hypertension in COPD Source: Eur Respir Mon 2013; 59: 189-205 Year: 2013 Bosentan therapy for portopulmonary hypertension Source: Eur Respir J 2005; 25: 502-508 Year: 2005 Survival with first-line bosentan in patients with primary pulmonary hypertension Source: Eur Respir J 2005; 25: 244-249 Year: 2005 Switch of patients with pulmonary arterial hypertension after withdrawal of the endothelin receptor antagonist sitaxentan Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension Source: Eur Respir J 2009; 33: 92-98 Year: 2009 Single centre experience with endothelin receptor blockade in pulmonary hypertension Source: Annual Congress 2004 - Pulmonary hypertension Year: 2004